Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ACADVL, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ACADVL also known as VLCAD (Very Long-Chain Acyl-CoA Dehydrogenase) is an enzyme that plays an important role in the breakdown of long-chain fatty acids within the mitochondria. It has a molecular mass of approximately 70 kDa. VLCAD is expressed in various tissues with high levels found in the heart skeletal muscle and liver. These tissues are heavily reliant on fatty acid oxidation for energy production especially when glucose availability is low.
Biological function summary
ACADVL functions within the mitochondrial matrix where it catalyzes the initial step of beta-oxidation by desaturating long-chain acyl-CoA molecules. This enzyme is a part of a larger complex that includes other mitochondrial dehydrogenases contributing to the degradation of fatty acids into acetyl-CoA units. The process is essential for energy production especially under fasting conditions or high-energy demand scenarios such as muscle contraction and cardiac function.
Pathways
VLCAD plays an essential role in the fatty acid beta-oxidation pathway. It works alongside other enzymes such as ACADM (Medium-Chain Acyl-CoA Dehydrogenase) to facilitate the sequential shortening of fatty acids which integrates into the Krebs cycle for further energy extraction. This pathway maximizes energy yield from fatty acids significantly influencing cellular metabolism and energy homeostasis.
VLCAD deficiencies lead to severe metabolic conditions such as VLCAD deficiency. This disorder results in the impaired breakdown of long-chain fatty acids causing energy deficiency and the accumulation of toxic substances. Symptoms range from muscle weakness to serious cardiac complications. VLCAD deficiency's impact is often assessed in relation to proteins like ACSL1 and CPT2 which are involved in the fatty acid metabolism pathway and are central to effective energy processing in cells.
